Literature DB >> 8569749

Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system.

R B Marala1, S J Mustafa.   

Abstract

The objective of this study was to determine whether adenosine A1 or A2 receptor was responsible for the regulation of protein kinase C (PKC) in porcine coronary artery and its coupling to G-protein. Endothelium denuded arterial rings were incubated with PDBu (200 nM) in the presence or absence of adenosine receptor agonists and antagonists for 1 day. Following incubation, the arterial rings were contracted with increasing concentrations of endothelin-1 (ET-1) (10(-10)-10(-7) M). Arteries incubated with PDBu alone failed to produce contraction in response to ET-1. On the contrary, inclusion of A1 receptor agonist ENBA at 10(-9) M in the incubation media with PDBu protected against the PDBu induced blunting of the ET-1 contractions by 50%. Incubation with ENBA alone increased ET-1 dependent contractions by about 2 fold. Inclusion of A1 receptor antagonist, N0861 at 10(-6) M along with PDBu and ENBA, completely blocked the protective effect of ENBA against the PDBu induced attenuation of ET-1 contractions. N0861 also completely blocked the increase in ET-1 contractions in the arterial rings incubated with ENBA alone. Another A1 receptor antagonist DPCPX also produced similar results as N0861. On the contrary, arterial rings incubated with relatively specific A2 receptor agonist CGS 21680 at 10(-4) M did not produce any protection against PDBu induced blunting of the ET-1 contractions. Incubation with CGS 21680 alone also did not significantly alter the ET-1 contractions. Interestingly, inclusion of A2 receptor antagonist DMPX at 10(-4) M in the incubation media along with CGS 21680 mimicked the effects of ENBA alone i.e. produced protection against PDBu and enhanced ET-1 contractions. Incubation of the arteries with ENBA alone caused an accumulation of PKC levels, whereas, incubation with CGS 21680 had no significant effect on PKC levels. To study the coupling of adenosine receptor with G-protein, the tissue was incubated for one day with cholera (CT) or pertussis toxin (PT) in the presence or absence or ENBA and PDBu as described above. Incubation with PT blocked the protective effect of ENBA against PDBu as well as the elevation of ET-1 response when incubated with ENBA alone. On the contrary, incubation with CT did not produce any significant effect on ENBA responses. These results indicate that PKC is modulated by adenosine via A1 adenosine receptors and through a PT sensitive G-protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8569749     DOI: 10.1007/bf01076563

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  49 in total

1.  RFL9 encodes an A2b-adenosine receptor.

Authors:  S A Rivkees; S M Reppert
Journal:  Mol Endocrinol       Date:  1992-10

2.  Stimulation of phosphatidylinositol hydrolysis, diacylglycerol release, and gene expression in response to endothelin, a potent new agonist for fibroblasts and smooth muscle cells.

Authors:  L L Muldoon; K D Rodland; M L Forsythe; B E Magun
Journal:  J Biol Chem       Date:  1989-05-25       Impact factor: 5.157

3.  G proteins subserve relaxations mediated by adenosine receptors in human coronary artery.

Authors:  M H Sabouni; T Hussain; D J Cushing; S J Mustafa
Journal:  J Cardiovasc Pharmacol       Date:  1991-11       Impact factor: 3.105

4.  A1 adenosine receptors of bovine brain couple to guanine nucleotide-binding proteins Gi1, Gi2, and Go.

Authors:  R Munshi; I H Pang; P C Sternweis; J Linden
Journal:  J Biol Chem       Date:  1991-11-25       Impact factor: 5.157

5.  Fate of immunoprecipitable protein kinase C in GH3 cells treated with phorbol 12-myristate 13-acetate.

Authors:  R Ballester; O M Rosen
Journal:  J Biol Chem       Date:  1985-12-05       Impact factor: 5.157

6.  Pertussis toxin-catalyzed ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site.

Authors:  R E West; J Moss; M Vaughan; T Liu; T Y Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

7.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells.

Authors:  T J Resink; T Scott-Burden; F R Bühler
Journal:  Biochem Biophys Res Commun       Date:  1988-12-30       Impact factor: 3.575

9.  Adenosine reduces agonist-induced production of inositol phosphates in rat aorta.

Authors:  C J Long; T W Stone
Journal:  J Pharm Pharmacol       Date:  1987-12       Impact factor: 3.765

10.  Adenosine and 5'-chloro-5'-deoxyadenosine inhibit the phosphorylation of phosphatidylinositol and myosin light chain in calf aorta smooth muscle.

Authors:  S R Doctrow; J M Lowenstein
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

View more
  3 in total

Review 1.  Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology.

Authors:  S Jamal Mustafa; R Ray Morrison; Bunyen Teng; Amir Pelleg
Journal:  Handb Exp Pharmacol       Date:  2009

2.  Isolation and characterization of coronary endothelial and smooth muscle cells from A1 adenosine receptor-knockout mice.

Authors:  Bunyen Teng; Habib R Ansari; Peter J Oldenburg; J Schnermann; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-18       Impact factor: 4.733

3.  Membrane Receptor-Induced Changes of the Protein Kinases A and C Activity May Play a Leading Role in Promoting Developmental Synapse Elimination at the Neuromuscular Junction.

Authors:  Josep M Tomàs; Neus Garcia; Maria A Lanuza; Laura Nadal; Marta Tomàs; Erica Hurtado; Anna Simó; Víctor Cilleros
Journal:  Front Mol Neurosci       Date:  2017-08-09       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.